Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis

(2020) Bruce A. C. Cree et al.   JAMA Neurology

Association between pathological and MRI findings in multiple sclerosis

(2019) Massimo Filippi et al.   LANCET NEUROLOGY

The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta‐analysis

(2019) Ting Yang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment

(2018) Claudio Solaro et al.   CNS DRUGS

Multiple sclerosis

(2018) Alan J Thompson et al.   LANCET

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis

(2018) Alexander Rae-Grant et al.   NEUROLOGY

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

(2017) Giancarlo Comi et al.   JOURNAL OF NEUROLOGY

Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis

(2017) Silvia Rossi et al.   NEUROLOGY

Defining secondary progressive multiple sclerosis

(2016) Johannes Lorscheider et al.   BRAIN

Multiple sclerosis

(2016) Brian Owens   NATURE

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis

(2016) Emer Fogarty et al.   Multiple Sclerosis and Related Disorders

The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS

(2015) Douglas R. Jeffery et al.   JOURNAL OF NEUROLOGY

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

Magnetic resonance outcome measures in multiple sclerosis trials

(2014) Massimo Filippi et al.   CURRENT OPINION IN NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

(2014) Edward Fox et al.   Multiple Sclerosis and Related Disorders

Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod

(2012) N.S. Roskell et al.   CURRENT MEDICAL RESEARCH AND OPINION

Multiple sclerosis relapses and depression

(2012) Phil Moore et al.   JOURNAL OF PSYCHOSOMATIC RESEARCH

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

(2012) T Saida et al.   Multiple Sclerosis Journal

Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis

(2011) B. Singer et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE